The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Evaluating salvage radiotherapy in patients with DLBCL
Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Monash University, Monash Health, Melbourne, Australia, discusses a study investigating whether patients with diffuse large B-cell lymphoma (DLBCL) can be salvaged with radiotherapy. Although there are novel approaches to DLBCL treatment, radiotherapy is more attractive, especially to older/frailer patients. Results demonstrated that 30-40% of patients with low volume disease could be salvaged with radiotherapy, avoiding the need to go through further toxic therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
